Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis

Sanjaya Satapathy, Puja Sakhuja, Veena Malhotra, Barjesh C. Sharma, Shiv K. Sarin

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Background and Aim: Inhibition of tumor necrosis factor (TNF)-α is a logical approach to manage patients with non-alcoholic steatohepatitis (NASH). Pentoxifylline reduces TNF-α and alanine aminotransferase (ALT) levels in patients with NASH. The aim of the present paper was to study if pentoxifylline can improve histological injury in patients with NASH. Methods: Nine patients (mean age 31.6 ± 7.2 years) with histologically proven NASH and with persistently elevated ALT (>1.5 times) were given pentoxyfylline at a dosage of 400 mg t.i.d. for 12 months. Besides biochemical assessment, a repeat liver biopsy was performed and the degree of inflammation and fibrosis was compared. Results: After 12 months of therapy a significant reduction in ALT (111 ± 53 IU/L vs 45 ± 19 IU/L, P = 0.003) and aspartate aminotransferase (AST) (61 ± 27 IU/L vs 33 ± 12 IU/L, P = 0.005) levels was observed. Steatosis and lobular inflammation each reduced in 55% and six (67%) patients down-staged on Brunt's staging (P = 0.009). Four out of six patients with baseline fibrosis had reduction in their fibrosis stage. Conclusions: Long-term pentoxyfylline therapy effectively achieves sustained biochemical improvement. This correlates well with histological resolution of the disease.

Original languageEnglish (US)
Pages (from-to)634-638
Number of pages5
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume22
Issue number5
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Pentoxifylline
Fatty Liver
Fibrosis
Liver
Alanine Transaminase
Tumor Necrosis Factor-alpha
Inflammation
Aspartate Aminotransferases
Biopsy
Wounds and Injuries
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. / Satapathy, Sanjaya; Sakhuja, Puja; Malhotra, Veena; Sharma, Barjesh C.; Sarin, Shiv K.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 22, No. 5, 01.01.2007, p. 634-638.

Research output: Contribution to journalArticle

@article{e0225d75a7a949acb7fab650e23b474d,
title = "Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis",
abstract = "Background and Aim: Inhibition of tumor necrosis factor (TNF)-α is a logical approach to manage patients with non-alcoholic steatohepatitis (NASH). Pentoxifylline reduces TNF-α and alanine aminotransferase (ALT) levels in patients with NASH. The aim of the present paper was to study if pentoxifylline can improve histological injury in patients with NASH. Methods: Nine patients (mean age 31.6 ± 7.2 years) with histologically proven NASH and with persistently elevated ALT (>1.5 times) were given pentoxyfylline at a dosage of 400 mg t.i.d. for 12 months. Besides biochemical assessment, a repeat liver biopsy was performed and the degree of inflammation and fibrosis was compared. Results: After 12 months of therapy a significant reduction in ALT (111 ± 53 IU/L vs 45 ± 19 IU/L, P = 0.003) and aspartate aminotransferase (AST) (61 ± 27 IU/L vs 33 ± 12 IU/L, P = 0.005) levels was observed. Steatosis and lobular inflammation each reduced in 55{\%} and six (67{\%}) patients down-staged on Brunt's staging (P = 0.009). Four out of six patients with baseline fibrosis had reduction in their fibrosis stage. Conclusions: Long-term pentoxyfylline therapy effectively achieves sustained biochemical improvement. This correlates well with histological resolution of the disease.",
author = "Sanjaya Satapathy and Puja Sakhuja and Veena Malhotra and Sharma, {Barjesh C.} and Sarin, {Shiv K.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1111/j.1440-1746.2006.04756.x",
language = "English (US)",
volume = "22",
pages = "634--638",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis

AU - Satapathy, Sanjaya

AU - Sakhuja, Puja

AU - Malhotra, Veena

AU - Sharma, Barjesh C.

AU - Sarin, Shiv K.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Background and Aim: Inhibition of tumor necrosis factor (TNF)-α is a logical approach to manage patients with non-alcoholic steatohepatitis (NASH). Pentoxifylline reduces TNF-α and alanine aminotransferase (ALT) levels in patients with NASH. The aim of the present paper was to study if pentoxifylline can improve histological injury in patients with NASH. Methods: Nine patients (mean age 31.6 ± 7.2 years) with histologically proven NASH and with persistently elevated ALT (>1.5 times) were given pentoxyfylline at a dosage of 400 mg t.i.d. for 12 months. Besides biochemical assessment, a repeat liver biopsy was performed and the degree of inflammation and fibrosis was compared. Results: After 12 months of therapy a significant reduction in ALT (111 ± 53 IU/L vs 45 ± 19 IU/L, P = 0.003) and aspartate aminotransferase (AST) (61 ± 27 IU/L vs 33 ± 12 IU/L, P = 0.005) levels was observed. Steatosis and lobular inflammation each reduced in 55% and six (67%) patients down-staged on Brunt's staging (P = 0.009). Four out of six patients with baseline fibrosis had reduction in their fibrosis stage. Conclusions: Long-term pentoxyfylline therapy effectively achieves sustained biochemical improvement. This correlates well with histological resolution of the disease.

AB - Background and Aim: Inhibition of tumor necrosis factor (TNF)-α is a logical approach to manage patients with non-alcoholic steatohepatitis (NASH). Pentoxifylline reduces TNF-α and alanine aminotransferase (ALT) levels in patients with NASH. The aim of the present paper was to study if pentoxifylline can improve histological injury in patients with NASH. Methods: Nine patients (mean age 31.6 ± 7.2 years) with histologically proven NASH and with persistently elevated ALT (>1.5 times) were given pentoxyfylline at a dosage of 400 mg t.i.d. for 12 months. Besides biochemical assessment, a repeat liver biopsy was performed and the degree of inflammation and fibrosis was compared. Results: After 12 months of therapy a significant reduction in ALT (111 ± 53 IU/L vs 45 ± 19 IU/L, P = 0.003) and aspartate aminotransferase (AST) (61 ± 27 IU/L vs 33 ± 12 IU/L, P = 0.005) levels was observed. Steatosis and lobular inflammation each reduced in 55% and six (67%) patients down-staged on Brunt's staging (P = 0.009). Four out of six patients with baseline fibrosis had reduction in their fibrosis stage. Conclusions: Long-term pentoxyfylline therapy effectively achieves sustained biochemical improvement. This correlates well with histological resolution of the disease.

UR - http://www.scopus.com/inward/record.url?scp=34247210640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247210640&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2006.04756.x

DO - 10.1111/j.1440-1746.2006.04756.x

M3 - Article

VL - 22

SP - 634

EP - 638

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 5

ER -